Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
Nathan PettengillDuring his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology. Read more
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
Haleigh BehrmanDuring a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Haleigh BehrmanLacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Nathan PettengillDrs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies. Read more
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
Nathan PettengillWhile Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care. Read more
Breaking the Silence: The #HearHer Campaign for Women with Lung Cancer
Lauren Kiel, BS+more
Narjust Florez, MD, and Angela Morabito, BS, launched the #HearHer campaign to raise awareness about the increasing incidence of lung cancer among women and the frequent delays in diagnosis. Read more
Poet and ILCN Editor-in-Chief Corey Langer, MD, illustrates the build-up and anticipation surrounding the release of research data. Read more
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Heidi Nafman-OndaHeidi Nafman-Onda, founder of The White Ribbon Project, shares her experience discovering and grappling with the long-term effects of radiation therapy and addresses the need for coordinated survivorship care. Read more
Laura Greco of “Die, Cancer, Die!” Fame will be Remembered for her Passionate Patient Advocacy
Jill Feldman, MA+more
The legacies patients like Ms. Greco leave serve to remind the thoracic oncology community why its work is vital. Read more
Patient Advocate Ivy B. Elkins Leaves Lasting Legacy
Erin Jungmeyer+more
Ms. Elkins, co-founder of the EGFR Resisters advocacy group, will be remembered for her warm and energetic approach to furthering lung cancer research efforts. Read more